Why Lower Doses of Cancer Drugs Aren't Studied More - Bloomberg
Skip to content
Bloomberg the Company & Its ProductsThe Company & its ProductsBloomberg Terminal Demo RequestBloomberg Anywhere Remote LoginBloomberg Anywhere LoginBloomberg Customer SupportCustomer Support
BloombergConnecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world
For CustomersBloomberg Anywhere Remote LoginSoftware UpdatesManage Products and Account Information
SupportAmericas+1 212 318 2000EMEA+44 20 7330 7500Asia Pacific+65 6212 1000
CompanyAboutCareersInclusion at BloombergTech at BloombergPhilanthropySustainabilityBloomberg Beta
CommunicationsPress AnnouncementsPress Contacts
FollowFacebookInstagramLinkedInYouTube
ProductsBloomberg TerminalDataTradingRiskComplianceIndices
Industry ProductsBloomberg LawBloomberg TaxBloomberg GovernmentBloombergNEF
MediaBloomberg MarketsBloomberg TechnologyBloomberg PursuitsBloomberg PoliticsBloomberg OpinionBloomberg BusinessweekBloomberg Live ConferencesBloomberg RadioBloomberg TelevisionNews Bureaus
Media ServicesBloomberg Media DistributionAdvertising
CompanyAboutCareersInclusion at BloombergTech at BloombergPhilanthropySustainabilityBloomberg Beta
CommunicationsPress AnnouncementsPress Contacts
FollowFacebookInstagramLinkedInYouTube
ProductsBloomberg TerminalDataTradingRiskComplianceIndices
Industry ProductsBloomberg LawBloomberg TaxBloomberg GovernmentBloombergNEF
MediaBloomberg MarketsBloomberg TechnologyBloomberg PursuitsBloomberg PoliticsBloomberg OpinionBloomberg BusinessweekBloomberg Live ConferencesBloomberg RadioBloomberg TelevisionNews Bureaus
Media ServicesBloomberg Media DistributionAdvertising
BloombergConnecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world
For CustomersBloomberg Anywhere Remote LoginSoftware UpdatesManage Contracts and Orders
SupportAmericas+1 212 318 2000EMEA+44 20 7330 7500Asia Pacific+65 6212 1000
Sign InSubscribeSearchLive TVMarketsChevron DownEconomicsIndustriesTechPoliticsBusinessweekOpinionMoreChevron DownUS EditionChevron DownMenuSubscribeNewsletterPrognosisWhy Lower Doses of Cancer Drugs Remain ElusiveFacebookXLinkedInEmailLinkGiftExpandManinder Singh at his home in Delhi on May 10, 2025.Photographer: Robert LangrethFacebookXLinkedInEmailLinkGiftGift this articleContact us:Provide news feedback or report an errorConfidential tip?Send a tip to our reportersSite feedback:Take our SurveyNew WindowFacebookXLinkedInEmailLinkGiftBy Robert Langreth and Swati GuptaSeptember 25, 2025 at 10:03 AM UTCBookmarkSaveLock This article is for subscribers only. Hi, It’s Bob in New York and Swati in New Delhi. We talked to a man who illustrates how a radical new dosing regimen could bring powerful immune therapies to cancer patients in developing countries. More on him in a moment, but first ...In wealthy countries, powerful immunotherapy drugs like Bristol Myers Squibb’s Opdivo and Merck’s Keytruda have revolutionized the treatment of melanoma over the last decade, sometimes extending survival by years.HomeBTV+Market DataOpinionAudioOriginalsMagazineEventsNewsMarketsEconomicsTechnologyPoliticsGreenCryptoAIWork & LifeWealthPursuitsBusinessweekCityLabSportsEqualityManagement & WorkMarket DataStocksCommoditiesRates & BondsCurrenciesFuturesSectorsEconomic CalendarExploreNewslettersExplainersPointed News QuizThe Big TakeGraphicsSubmit a TipAbout UsTerms of ServiceDo Not Sell or Share My Personal InformationTrademarksPrivacy PolicyCareersMade in NYCAdvertiseAd ChoicesHelp©2025 Bloomberg L.P. All Rights Reserved.